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Introduction
Recent progress in understanding the molecular basis of cancer has redefined the landscape for achieving stratified and personalized medicine for cancer patients. Ongoing efforts concentrate on the translation of these molecular insights into biomarkers that can reliably guide application of existing and new cancer treatments.
Biomarkers that are informative for selecting treatment can be broadly classified as prognostic or predictive biomarkers. Prognostic biomarkers classify patients treated with standard therapiesincluding no treatment, if that is standard practice -into subgroups with distinct expected clinical outcomes. Predictive biomarkers identify patients whose tumors are likely to be sensitive or resistant to a specific agent. A rapid review of the biomarker trial designs in the oncology literature suggests substantial variability in the designs, as well as in the terms proposed by authors for labeling them. This makes retrieval, interpretation, comparison and critical appraisal of these types of studies complicated for consumers of trial results, who can be practicing physicians, researchers or policymakers. The variability in labeling is a phenomenon typical for many rapidly developing areas of science. However, now that the field is maturing, and experts in other fields of medicine, such as cardiovascular diseases and infectious diseases, have started to apply the methodological achievements of the oncology biomarker trials, it is time for harmonizing the terminologies in use and framing a classification of the designs. A harmonized terminology for describing biomarker clinical trials and a simple classification scheme may help in speeding up the translation process of the biomarker findings and could assist in paving the way for making personalized medicine a reality.
Here we report on a systematic review of literature on trial designs for evaluating biomarkers for treatment selection. The review is based on a comprehensive and systematic search in multiple databases. We propose a classification scheme based on the flow of patients in these trials. The classification system is presented using recent biomarker clinical trials in oncology as examples, along with the main questions each category of designs can answer.
Methods

Literature search
We searched MEDLINE, EMBASE, Cochrane Methodology Register and MathSciNet up to 15 January 2013, and handsearched references and citing articles of all included studies using the Web of Science database. The search filters that we developed and employed in collaboration with a clinical librarian are presented in the Supplemental Materials and Methods. Eligible for inclusion were methodological articles that described one or more trial designs for identification and/or validation of prognostic or predictive biomarkers for treatment selection. The search was not limited to oncology. No language restrictions were applied.
One author (P.T.) independently identified potentially eligible articles by reading titles and abstracts while a second author (P.B.) independently screened a random sample of 400 abstracts to ensure that no abstracts were missed. There was a 99% agreement on the selection of abstracts and disagreements were resolved in consensus discussions. Thereafter, full text copies of all potentially eligible articles were obtained and read in full. Articles were included if they satisfied the inclusion criteria.
Data Extraction
From all included articles and for each proposed trial design we extracted detailed data on the proposed design label, trial objectives, patient flow elements, and the analysis plan. Our definition of patient flow is composed of the biomarker status of participants deemed eligible for the study, the intervention participants are assigned to (whether or not biomarker status is used for assigning study participants to the experimental treatment) and the comparator (standard treatment or both standard and experimental treatments).
Analysis
We started our analysis by developing the list of study labels from all included studies. For each label in the list we explored the participant-intervention-comparator components of patient flow. We then clustered all study labels with identical components into disjoint categories. The most commonly used label for describing designs of each category was selected for labeling the corresponding category.
Our initial search yielded 2,506 abstracts, of which 136 were deemed eligible based on title and abstract. After assessing the full texts of these 136 articles, 71 were included. Seventeen other articles were added by handsearching references and citing articles, resulting in a total of 88 articles in the final analysis (Supplementary Table 1) . A summary of the search process is outlined in the Figure 1 .
Trial design labels
From the included articles we could extract 315 design labels. The identified labels and the definitions as presented in the studies are listed in the Supplementary Table 2 . By analyzing the extracted labels along with their patient flow components we found 134 unique combinations of label and patient flow elements. There were many trial designs with the very same patient flow elements, which had received different labels. There were also a few labels used for describing designs with completely different patient flows. The 134 unique label and patient flow combinations are presented in Table 1 . By comparing the patterns of all the included designs we could distinguish four basic and distinct patient flow categories, as well as a fifth category, consisting of combinations of two or more of the four basic patient flow elements (Table 1 ). In the section below, we discuss these categories in more detail.
Trial design categories
To ease the presentation, we present the flow elements for two treatment options, labeled as experimental (Exp) and control (Ctrl), in the presence of a single, binary biomarker (Figure 2) . However, the flow diagrams are generalizable to conditions with more than two treatment options and in which the biomarker has more than two levels, or is numeric. For sake of simplicity and consistency we define biomarker positivity as the biomarker status that is associated with a better outcome on the experimental treatment. Therefore, in cases where overexpression of the biomarker is associated with a worse response to treatment, we consider the normal expression as biomarker positive and overexpression as biomarker negative.
I. Single-arm
In single-arm trials, all patients, irrespective of their biomarker status, are included in the trial and all undergo the experimental treatment ( Figure 2a) . (4) (5) (6) (7) (8) This trial has no control group, and no random assignment.
II. Enrichment
With an enrichment design, all potentially eligible patients are first tested for the biomarker and only biomarker positives are randomly assigned to the experimental or control treatment. Other patients are in principle excluded from further investigation in the study (Fig 2b) . We found 12 labels for describing this design, which were all interchangeable and referred to the main feature of the design: biomarker status performs as a key trial eligibility criterion ( Table 1 ).
The pivotal trial for trastuzumab is a well-known example of an enrichment design. (9) Patients with HER2-positive breast adenocarcinoma (human epidermal growth factor receptor2) were enrolled and randomly allocated to chemotherapy with or without trastuzumab. This study provided strong evidence that trastuzumab combined with chemotherapy improves outcomes among women with HER2-positive breast cancer.
III. Randomize-all
Research. In designs in the randomize-all category, all patients meeting the trial eligibility criteria, irrespective of their biomarker status, are randomly allocated to either experimental or control treatment. Afterwards associations between biomarker status and treatment response are evaluated. (Figure 1c) Because its eligibility criteria is not restricted by biomarker status, it has commonly been labelled as 'randomize-all'(2, 10-13), 'all-comers'(14-18) or 'untargeted' (19, (19) (20) (21) (22) .The design is also called 'traditional' (23) (24) (25) or 'conventional' (1, 26) because it has the same patient flow elements as routine randomized controlled trials (RCT) for evaluating treatment options. It is possible that researchers evaluate a biomarker retrospectively, using data and stored biospecimens collected in previously completed RCT's. In such scenarios trials are commonly labelled as 'biomarker analysis within an existing RCT' (18) or 'prospective/retrospective' (27) . All these label variations mainly refer to the timing of introducing the biomarker question to the trial.
The type of randomization is another source of variability in labelling of randomize-all trials. In cases where a simple 1:1 randomization procedure is applied to all patients, trials are labelled as 'simple randomization' (28) . However, in cases where the biomarker under evaluation is binary or categorical with few categories, randomization can be done separately for each biomarker category through stratified randomization. Labels such as 'biomarker-stratified' (29, 30) , 'stratified randomized'(31), 'non-targeted RCT (stratified by marker)'(32), 'stratified analysis' (25) , ' stratification' (33, 34) and 'separate randomization' (35) , all refer to this type of randomization. A special case of stratified randomization is when randomization is performed by means of a Bayesian response-adaptive procedure, rather than a standard equal randomization procedure. The 'Bayesian adaptive randomization design'(36) by Zhou and colleagues is an example. It has been also called 'outcome- 
V. Biomarker-strategy
The distinguishing feature of designs in the biomarker-strategy category is the inclusion of a new management strategy. This strategy is not the standard or experimental treatment, but a prespecified maker-based treatment strategy. For example, biomarker-positive patients would receive experimental therapy while all biomarker-negative patients get standard of care. Eligible patients are randomized to this biomarker-based treatment strategy or to control treatment. In our review we could identify three subtypes of this category.
a. Biomarker-strategy, with biomarker assessment in the control arm(1)
Biomarker status is assessed in all patients enrolled in the trial, who are then randomly allocated to either the biomarker-strategy arm or to standard treatment (Figure 2d ). Some other labels for this design type were Biomarker-strategy (15, 38, 44) , 'marker-based strategy I'(45), 'customized strategy' (12) , 'direct predictive biomarker-based'(46) and 'biomarker-guided' (47) . There were also other labels in use, such as 'random disclosure'(48), 'classifier randomization' (49) or 'parallel controlled phrmacogenetic study'(50).
b. Biomarker-strategy, without biomarker measurement in the control arm
In settings where it is not feasible or ethical to evaluate the biomarker in all patients, biomarker status is only acquired in patients allocated to the biomarker-strategy arm (Figure 2e ). This design is also labelled as 'biomarker-strategy with standard control'(2), Direct predictive biomarker-based(46), 'RCT of testing'(48), 'test-treatment'(51), or 'parallel controlled pharmacogenetic diagnostic study' (50) . 
Effects assessed by each category of designs
There are four types of effects we are commonly interested in when designing a biomarker trial; the treatment effect, the biomarker effect, the biomarker by treatment effect, and the strategy effect. These are presented with eight study questions in Table 2 . The treatment effect (experimental versus control) can be estimated separately for biomarker-positive patients (Q1), for biomarker-negative patients (Q2) and in the overall population (Q3). Single-arm trials do not answer any of these questions, since they lack a control arm to allow comparisons. Enrichment trials recruit biomarker-positive patients and allocate them to experimental or control treatment thus letting us evaluate the effect of treatment, but only in biomarker-positive patients (Q1).(1) Randomize-all trials recruit patients from the whole spectrum of the biomarker values and allocate them randomly to either of the two treatment options.
Therefore they allow estimation of the treatment effect in biomarker-positives, biomarker-negatives, and in the overall population (Q1-3).
To evaluate if a biomarker is prognostic (Q4), one needs to compare the outcome of biomarkerpositive and biomarker-negative patients on control treatment; a comparison which is possible in randomize-all study designs but not in single-arm or enrichment trials. (1, 28) . The only effect one can estimate in single-arm trials is the biomarker effect in the experimental arm; whether biomarker status is associated with the outcome of experimental treatment (Q5).
To assess the predictive capacity of a biomarker (Q8) -the biomarker by treatment effect -one needs to have the outcome of biomarker-positive and biomarker-negative patients separately after 
Discussion
This systematic review documented a substantial variability in the labeling of clinical trial designs for evaluating biomarkers for treatment selection in individual patients. We identified more than three hundred labels, half of which were unique. In evaluating the heterogeneity in design labels we used a classification scheme based on patient flow components of the corresponding trial designs. Under each of the four basic patient flow categories several labels could be categorized; where some labels are completely interchangeable terms. Other designs, while having the same patient flow elements, carried specific objectives or had diverging analysis plans, which authors have labeled them differently, to emphasize these distinctive aspects.
Using our patient flow scheme one would be able to classify biomarker trial designs into a small set of basic categories. This could be useful for identifying similarities between novel designs and existing ones, or to evaluate proposed modifications of existing designs. It could also be helpful in reducing the confusion around the design of biomarker trials and help with standardizing the reporting of biomarker clinical trials. Since the classification is based on patient flow, it is directly connected to the possible comparisons that can be made in the trial and, consequently, the questions that could be potentially answered by the trial.
By comparing the designs in Table 2 , a biomarker-strategy design with treatment randomization in the control arm seems a very attractive option, allowing for direct estimation of all biomarker related effects, yet this feature might come at the cost of a large sample size. Nevertheless, in situations where the biomarker-strategy is complex -has a large number of treatment options or biomarker categoriesor when the trial is planned primarily for confirmatory assessment of a specific biomarker-based strategy, a biomarker-strategy trial can be the design of choice.
Randomize-all trials also allow assessment of all biomarker related effects, but provide indirect estimates of strategy effects. An attractive aspect of randomize-all trials is that they allow identification and evaluation of biomarkers that were not specified in the design phase of the trial. Single or multiple biomarkers can be studied and multi-marker models can be developed and tested in trials of randomize-all category. If one collects and stores biological specimens from participants of a randomize-all trial in biobanks, the trial data can be used later on to identify or evaluate single or multiple biomarkers, possibly not even known at the time of trial design.(57) A limitation of biomarkerstrategy trials is that assessments are restricted to a prespecified biomarker-treatment combination strategy and they can not be used for further identification or validation of other biomarkers. However, 
since all analyses which emerge after designing the trial are considered post-hoc and exploratory, cross-validation and/or independent validation approaches are required to establish the utility of biomarkers.
Enrichment design can be selected when there is strong prior biological evidence that the experimental treatment has no effect in biomarker negative patients. (3, 20) Yet, a positive trial does not prove the utility of the biomarker because there may exist a positive treatment effect in the unevaluated biomarker-negative patients. (1) (3) Biomarker trials have predominantly been proposed and discussed in the setting of phase III trials in oncology. All categories identified in this review apply when designing a phase III biomarker trial, though some designs have been suggested primarily for a phase II setting. These include randomize-all designs with adaptive randomization, such as the outcome-based trials with Bayesian adaptive randomization (5, 36) , as well as some of the designs in the combined category, such as tandem two-step phase II predictor marker evaluation (58) , which aim at finding a promising treatment/biomarker pair that can be moved forward to a phase III evaluation.
To our knowledge, this review is the first systematic review of trial designs for evaluation of prognostic and predictive biomarkers. Several other narrative reviews are available, most often written by experts, (1, 2, 33, 35, 52 ) who commonly have discussed a selected series of biomarker trial designs and used their personally preferred design labels. Yet our review was also not without limitation, which was the shortcomings of our search strategy in the electronic databases. The retrieval of methodological articles is challenging because no specific keywords are available to distinguish articles that have described or presented a method from those which have just applied that method. Most of the search terms we could use were non-specific. Even the terms 'prognostic' and 'predictive' are commonly used by authors in other situations. To compensate for these challenges we designed our 
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